<DOC>
	<DOCNO>NCT00203632</DOCNO>
	<brief_summary>The purpose study determine addition rosiglitazone subject fair glucose control oral agent improve endothelial function , surrogate marker vascular health . It hypothesize improve whole body insulin sensitivity combination therapy include rosiglitazone restore vascular action insulin improve endothelium-dependent vasomotion effectively placebo patient diabetes mellitus .</brief_summary>
	<brief_title>Glitazones Endothelial Function ( GATE )</brief_title>
	<detailed_description>The vascular endothelium emerge critical determinant cardiovascular health disease , improve endothelial function important target therapy . Accumulating evidence suggest insulin resistance patient diabetes metabolic syndrome may impair endothelial function , uncover proinflammatory , proatherosclerotic vascular phenotype . The GATE study ( Glitazones And The Endothelium ) randomize , double blind study evaluate effect rosiglitazone vs. placebo endothelial function employ add-on therapy diabetic patient currently treat oral therapy . We hypothesize PPAR-gamma agonist rosiglitazone , improve endothelium-dependent vasodilatation , effect related improvement insulin sensitivity , concomitant reduction whole body insulin resistance . Furthermore , beneficial effect rosiglitazone additive exist oral therapy may modulate endothelial function , metformin . Since endothelial dysfunction play pivotal role development progression atherosclerosis , study may provide rationale impetus aggressive treatment insulin resistant patient glitazone therapy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>All patient ( men woman ) consider participation GATE study noninsulin dependent diabetic ( accord Canadian Diabetes Association criterion , namely fast serum glucose ≥ 7.0 mmol/L two occasion , casual glucose ≥ 11.1 mmol/l symptom , 2h postoral glucose tolerance test glucose ≥ 11.1 mmol/l ) unsatisfactory glycemic control oral therapy ( HbA1c 610 % ) . Exclusion criterion include , congestive heart failure ( NYHA class III &amp; IV ejection fraction le 35 % ) , poorly control hypertension ( blood pressure &gt; 160/90 ) , hypercholesterolemia ( total cholesterol &gt; 6.2 mmol/l ) , hypertriglyceridemia ( triglyceride &gt; 4.0 mmol/l ) , poor excellent control DM ( HgA1c &lt; 6 % HbA1c &gt; 10 % respectively ) , know diabetic retinopathy , age diagnosis diabetes less 25 year , current participation another clinical trial contraindication glitazones therapy , include renal ( creatinine &gt; 200 micromol/ L ) hepatic ( ALT &gt; 2.5 time upper limit normal ) impairment and/ know intolerance glitazones . Patients must stable medication affect endothelial function one month . This include ACEinhibitors , angiotensin receptor blocker , statin , calcium channel blocker , hormone replacement therapy antioxidant vitamin , include folate . Patients insulin exclude . Patients felt attainment good glucose control require within 3 month also exclude . Patients stable coronary disease eligible study long &gt; one month post myocardial infarction , percutaneous intervention bypass surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>endothelium</keyword>
	<keyword>thiazolidinediones</keyword>
	<keyword>atherosclerosis</keyword>
</DOC>